C. Diazzi

E. Magnani

L. Volpi

M. L. Monzani

S. Pederzoli

V. Rochira

English

V. Rochira.

Archivio istituzionale della ricerca - Università di Modena e Reggio Emilia

	 	  	Downloaded from https://academic.oup.com/jes/issue/3/Supplement_1 by Endocrine Society Member Access 3 user on 22 June 2019Article NavigationSUN-464 Trunk Fat Increase Is Prevented Both inPatients Undergoing Long-Lasting Continuous r-hGHTherapy and in Those Who Discontinued r-hGHCompared to Untreated Patients: Results from BaselineData of the MAGHD Study Maria Laura Monzani, MD, Elisa Magnani, MD, Chiara Diazzi, MD, PhD, Laura Volpi,Vincenzo Rochira, MD, PhDJournal of the Endocrine Society, Volume 3, Issue Supplement_1, April-May 2019, SUN-464,https://doi.org/10.1210/js.2019-SUN-464Published:  30 April 2019AbstractSplit View Cite Permissions Share Background: Adult-onset growth hormone (GH) deficiency (AGHD) is related withalterations in body composition, increased abdominal and visceral adiposity, adversechange in lipid and carbohydrate metabolism, and reduction of bone mineral density(BMD). Aim: To compare body composition and biochemical/hormonal data amongadult patients with AGHD referring to a single endocrinological center and groupedaccording to r-hGH therapy. Methods: The Manage Growth Hormone DeficiencyStudy (MAGHD) is a prospective, single-center trial aiming to improve AGHDmanagement through a smartphone app (MAGHD App: Manage AGHD) integratedwith a software framework able to merge several kind of patients’ daily data withclinical data collected in institutional databases. Up-to-now, a total of 74 subjects (26Female, 48 Male, mean age: 56.6+14.8 years) with AGHD, fulfilling the inclusioncriteria, were enrolled in the study. According to r-hGH therapy, they were divided in 3  View MetricsEmail alertsNew issue alertIn progress issue alertIssue Section:  Neuroendocrinology and PituitaryCopyright © 2019 Endocrine SocietyThis article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).groups: patients on long-term r-hGH therapy (Group 1, n=33), patients previouslytreated with r-hGH, who had stopped the therapy at any time (Group 2, n=18),patients never treated (Group 3, n=23). Each patient has completed the baseline visit,including biochemical and hormonal measurements and data on BMD and bodycomposition obtained by DXA. The nonparametric Kruskal-Wallis test was used forcomparison among 3 groups and data are expressed as median. Results: Meanduration of AGHD disease of the entire cohort was 121.2+105.8 months; it was lower inGroup 3 compared to both Group 1 and 2 (p<0.05). Waist circumference (Group 1 95cm; Group 2 96,5 cm; Group 3 109 cm) and trunk fat mass (Group 1 539 g; Group 2 525g; Group 3 595 g) were significantly higher in Group 3 compared to both Group 2 and 1(p<0.05). Serum insulin, total fat mass, and total body fat (%) were significantlyhigher in Group 3 than Group 1 (p<0.05). IGF-1 and IGFBP3 were significantly higherin Group 1 compared to both Group 2 and 3 (p<0.0001). BMD, circulating lipids, andfasting glucose did not di!er among the 3 groups. Conclusions: r-hGH therapy seemsto confer a long-lasting beneficial e!ect on body fat, especially trunk fat even after itsdiscontinuation in AGHD patients, but not on metabolic parameters.Acknowledgment: This clinical study is conducted thanks to the competitiveassignment of an Independent Grant for Learning & Change (“IGCL”) Dissemination& Implementation (“D&I”) by Pfizer Inc.

Trunk Fat Increase Is Prevented Both in Patients Undergoing Long-Lasting Continuous r-hGH Therapy and in Those Who Discontinued r-hGH Compared to Untreated Patients: Results from Baseline Data of the MAGHD Study

CO Ϭϳϱ Ͳ TRUNK FAT INCREASE IS PREVENTED BOTH IN PATIENTS UNDERGOING LONGͲLASTING  CONTINUOUS  RͲHGH  THERAPY  AND  IN  THOSE  WHO  DISCONTINUED  RͲHGHCOMPARED TO UNTREATED PATIENTS͗ RESULTS FROM BASELINE DATA OF THE MAGHDSTUDY͘M͘ L͘ MŽŶǌaŶiϭ͕ E͘ MagŶaŶiϭ͕ C͘ Diaǌǌiϭ͕ S͘ PedeƌǌŽůiϭ͕ L͘ VŽůƉiϭ͕ V͘ RŽchiƌaϭϭUŶiƚà OƉeƌaƚiǀa di EŶdŽcƌiŶŽůŽgia͕ UŶiǀeƌƐiƚà di MŽdeŶa e ReggiŽ Eŵiůia MŽdeŶaBacŬgƌŽƵŶd͗ Adult  growth  hormone  (GH)  deficiency  (AGHD)  is  related  with  alterations  in  bodycomposition, increased abdominal and visceral adiposity, adverse change in lipid and carbohydratemetabolism, and reduction of bone mineral density (BMD).Aŝŵ͗ To compare baseline outcomes concerning body composition and biochemical/hormonal dataamong adult patients with AGHD referring to a single endocrinological center and grouped according totheir history of r-hGH therapy.MeƚŚŽdƐ͗ The Management of Adult Growth Hormone Deficiency Study ;MAGHD) is a prospective,single-center trial aiming to improve AGHD management through a smartphone app (MAGHD App:Manage AGHD) and a wearable device integrated with a software framework able to merge severalkind of patients’ daily data with clinical data collected in institutional databases.Up-to-now, a total of ϳϰ subjects (Ϯϲ Female, ϰϴ Male, mean age: ϱϲ.ϲнϭϰ.ϴ years) with AGHD, fulfillingthe inclusion criteria, were enrolled in the study. According to r-hGH therapy, they were divided in ϯgroups: patients on long-term r-hGH therapy (Group ϭ, nсϯϯ), patients previously treated with r-hGH,who had stopped the therapy at any time (Group Ϯ, nсϭϴ), patients never treated (Group ϯ, nсϮϯ). Eachpatient has completed the baseline visit, including biochemical and hormonal measurements and dataon BMD and body composition obtained by DXA. The nonparametric Kruskal-Wallis test was used forcomparison among ϯ groups and data are expressed as median. Only baseline data are here shown.ReƐƵůƚƐ͗ Mean duration of AGHD disease of the entire cohort was ϭϮϭ.ϮнϭϬϱ.ϴ months; it was lower inGroup ϯ compared to both Group ϭ and Ϯ (pфϬ.Ϭϱ). Waist circumference (Group ϭ ϵϱ cm; Group Ϯ ϵϲ,ϱcm; Group ϯ ϭϬϵ cm), total fat mass (Group ϭ ϮϱϬϭϲ g; Group Ϯ Ϯϲϰϵϭ g; Group ϯ ϯϯϴϴϳ g) and trunk fatmass (Group ϭ ϭϭϳϰϯ g;  Group Ϯ ϭϮϱϵϴ g;  Group ϯ ϭϲϳϲϭ g)  were significantly higher in Group ϯcompared to both Group Ϯ and ϭ (pфϬ.Ϭϱ),  while total  fat mass and trunk fat mass did not differsignificantly among Group ϭ and Ϯ. Serum insulin and total body fat (й) were significantly higher inGroup ϯ than Group ϭ (pфϬ.Ϭϱ). IGF-ϭ and IGFBPϯ were significantly higher in Group ϭ compared toboth Group Ϯ and ϯ (pфϬ.ϬϬϬϭ). BMD, circulating lipids, and fasting glucose did not differ among the ϯgroups.CŽŶcůƵƐŝŽŶƐ͗ r-hGH therapy seems to confer a long-lasting beneficial effect on body fat, especially trunkfat, even after its discontinuation in AGHD patients, but not on metabolic parameters.AcŬŶŽǁůedgŵeŶƚ͗ This  clinical  study  is  conducted  thanks  to  the  competitive  assignment  of  anIndependent Grant for Learning Θ Change (“IGCL”) Dissemination Θ Implementation (“DΘI”) by PfizerInc.

Trunk fat increase is prevented both in patients undergoing long- lasting continuous r-hGH therapy and in those who discontinued r-hGH compared to untreated patients: results from baseline data of the MAGHD study

Trunk fat increase is prevented both in patients undergoing long-lasting continuous r-hGH therapy and in those who discontinued r-hGH compared to untreated patients: results from baseline data of the MAGHD study

https://iris.unimore.it/bitstream/11380/1199371/1/0119_Monzani_et_al_CO075_40_Congresso_Nazionale_SIE_2019_Roma.pdf

Trunk fat increase is prevented both in patients undergoing long- lasting continuous r-hGH therapy and in those who discontinued r-hGH compared to untreated patients: results from baseline data of the MAGHD study

Abstract

Similar works

Full text

Available Versions

Archivio istituzionale della ricerca - Università di Modena e Reggio Emilia

Archivio istituzionale della ricerca - Università di Modena e Reggio Emilia

Archivio istituzionale della ricerca - Università di Modena e Reggio Emilia